Sygnia founder Magda Wierzycka lifts lid on how her company bought into Oxford’s Covid-19 vaccine

Loading player...
UPDATE: The headline has been changed to make it clear that neither Sygnia nor any other investors funding the development of the vaccine will profit from it during the pandemic. The return on investment will only come in future years - IF the vaccine works. We sincerely apologise for the previous headline creating the wrong impression. - Editor 
Sygnia founder and CEO Magda Wierzycka, is among a handful of SA business leaders who truly sees the world as her oyster. Well known for her forward thinking, she in 2015 bought shares in OSI, a company that transforms patents from Oxford University into viable businesses for 25% ownership. Within the OSI stable is Vaccitech, a company that has been developing a vaccine for MERS virus and has put them ahead of the Covid-19 vaccine race. Sygnia, the single biggest shareholder of OSI, is well placed to reap the rewards once the vaccine is made commercial. - Vanessa Marks Learn more about your ad choices. Visit megaphone.fm/adchoices
5 May 2020 11AM English South Africa Investing · Business News

Other recent episodes

To study or to start a business? The choice that built Bubbadue

More than one in 10 university graduates in South Africa cannot find a job. With an economy that creates far too few jobs for the people entering it, and AI starting to eat into white-collar work, many school leavers and their parents are asking whether a degree is still the…
20 Nov 5AM 14 min

BN Edge | Michael Beaumont on ActionSA's coalition hand and the DA standoff

Michael Beaumont has been called the power behind ActionSA's throne, and he's the man running its coalition talks across Gauteng. Speaking to Alec Hogg hours before ActionSA's first sit-down with the DA, he said the DA had never once come to the table until then, and that his party had…
19 Nov 9AM 50 min